High rates of retention for secukinumab in plaque psoriasis: study
Efficacy was sustained for patients for up to three years, according to observational data
Secukinumab therapy for moderate to severe plaque psoriasis is associated with high rates of long-term retention and sustained efficacy, real-world patient data show.
Results from the longitudinal European SERENA study — funded by secukinumab sponsor Novartis — show that nearly two-thirds of patients persist with the monoclonal antibody for up to three years, with minimal impact from treatment interruption.
